Mohammadmehdi Adhami, MD, presented “Oral Abstracts – Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE Registry” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 17, 2024, in San Diego, California.
>
How to cite: Adhami, Mohammadmehdi. “Oral Abstracts – Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE Registry.” October, 2024. Accessed Jan 2025. https://grandroundsinurology.com/oral-abstracts-oncological-and-functional-outcomes-post-focal-low-dose-rate-brachytherapy-for-low-intermediate-risk-prostate-cancer-results-from-australias-liberate-registry/
Oral Abstracts – Oncological and Functional Outcomes Post Focal Low-Dose-Rate Brachytherapy for Low-Intermediate Risk Prostate Cancer – Results from Australia’s LIBERATE Registry – Summary
Mohammadmehdi Adhami offers a detailed exploration of focal brachytherapy outcomes for low to intermediate-risk prostate cancer. In this 6-minute presentation, Adhami analyzes the LIBERATE registry, a clinical register tracking 120 men undergoing focal low-dose-rate brachytherapy.
Adhami first highlights functional outcomes, with urinary, bowel, and erectile functions showing only mild initial impairment. The discussion then transitions to interpreting prostate-specific antigen (PSA) levels post-treatment.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
